Prophylactic Azithromycin Therapy After Lung Transplantation: Post hoc Analysis of a Randomized Controlled Trial

Effect of HMG CoA reductase inhibitors on the development of chronic lung allograft dysfunction

“…Chronic lung allograft dysfunction is a common complication postlung transplant and contributes to recipients’ low survival rate post‐transplant. To date, azithromycin has been one of the only strategies identified as potentially preventing the development of CLAD . Statins have previously been evaluated to identify their role in the management of BOS, but not their role in the development of CLAD.…”

Diagnosis and management of bronchiolitis obliterans syndrome following lung or hematopoietic cell transplantation

“…Additionally, longer term analysis of the treatment arms from this same RCT showed that prophylactic AZI was associated with significantly improved CLAD-free survival, pulmonary function, and functional exercise capacity versus the placebo group. [14] In contrast, a study of prophylactic AZI for allogeneic HCT recipients did not demonstrate an ability to prevent BOS, [15] but this study employed a non-randomized, retrospective design, and significant differences in baseline characteristics were present between the AZI and placebo groups.…”

Pirfenidone in restrictive allograft syndrome after lung transplantation: A case series

“…Per follow-up protocol, total lung capacity (TLC) (and diffusing capacity for carbon monoxide) measurements after LTx were only systematically performed on an annual basis in our center, or exceptionally for specific indications (ie, at RAS diagnosis, at start of pirfenidone, and so on), but not on a regular basis (ie, for instance, every 3 months, unlike spirometry), because of healthcare budget constraints in costs and personnel. 25 RAS was diagnosed using TLC (≥10% decrease compared to baseline, L), FVC (≥20% decline, L), and/or FEV 1 /FVC ratio (>0.70) in combination with persistent infiltrates on chest CT scan, as previously described. 7,13,21,25 CLAD was diagnosed as a persistent decline in forced expiratory volume in 1 second (FEV 1 ) (liter [L]) of at least 20% compared to the average of the 2 best postoperative values ("baseline"), without any other identifiable cause or confounding factors.…”

“…Chest CT and 18 F -FDG PET/CT imaging were performed as previously described. 25 Dates of CLAD, redo-transplantation, death, or graft loss (defined as redo-transplantation or death) and all other parameters were obtained from the patients' individual electronic clinico-pathological medical files at University Hospitals Leuven, and saved in a separate anonymized file at the University Lab of Respiratory Diseases. 25 RAS was diagnosed using TLC (≥10% decrease compared to baseline, L), FVC (≥20% decline, L), and/or FEV 1 /FVC ratio (>0.70) in combination with persistent infiltrates on chest CT scan, as previously described.…”

“…25,26 Briefly, all LTx recipients were in lifelong follow-up at 3-4-month intervals at our outpatient clinic. 25,26 Briefly, all LTx recipients were in lifelong follow-up at 3-4-month intervals at our outpatient clinic.…”